Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor- in macrophages

Journal of Biomedical Science

Volumn 16, Issue 1, 2009, Pages

  Shyu, Kou Gi ^a,b   Chua, Su Kiat ^a   Wang, Bao Wai ^a   Kuan, Peiliang ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ATORVASTATIN; GLUCOSE; MESSENGER RNA; MEVALONIC ACID; RAC PROTEIN; RESISTIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DETERMINATION; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELLS, CULTURED; GLUCOSE; HEPTANOIC ACIDS; HUMANS; MACROPHAGES; PROMOTER REGIONS, GENETIC; PYRROLES; RATS; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650498357     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-16-50     Document Type: Article

References (23)

1. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. S Verma SH Li CH Wang PW Fedak RK Li RD Weisel DA Mickle, Circulation 2003 108 736 740 10.1161/01.CIR.0000084503.91330. 49 12874180
2. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. D Kawanami K Maemura N Takeda T Harada T Nojiri Y Imai I Manabe K Utsunomiya R Nagai, Biochem Biophys Res Commun 2004 314 415 419 10.1016/j.bbrc.2003.12.104 14733921
3. Resistin, an adipokine with potent proinflammatory properties. M Bokarewa I Nagaev L Dahlberg U Smith A Tarkowski, J Immunol 2005 174 5789 5795 15843582
4. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. P Kougias H Chai PH Lin AB Lumsden Q Yao C Chen, J Vasc Surg 2005 41 691 698 10.1016/j.jvs.2004.12.046 15874935
5. The potential role of resistin in atherogenesis. MS Burnett CW Lee TD Kinnaird E Stabile S Durrani MK Dullum JM Devaney C Fishman S Stamou D Canos S Zbinden LC Clavijo GJ Jang JA Andrews J Zhu SE Epstein, Atherosclerosis 2005 182 241 248 10.1016/j.atherosclerosis.2005.02.014 16159596
6. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol 3-kinase pathways. P Calabro I Samudio JT Willerson ET Yeh, Circulation 2004 110 3335 3340 10.1161/01.CIR.0000147825.97879.E7 15545519
7. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. HS Jung KH Park YM Cho SS Chung HJ Cho SY Cho SJ Kim SY Kim HK Lee KS Park, Cardiovasc Res 2006 69 76 85 10.1016/j.cardiores.2005.09.015 16271710
8. Resistin is an inflammatory marker of atherosclerosis in humans. MP Reilly M Lehrke ML Wolfe A Rohatgi MA Lazar DJ Rader, Circulation 2005 111 932 939 10.1161/01.CIR.0000155620.10387.43 15710760
9. Toward immunomodulatory and anti-inflammatory properties of statins. C Arnaud V Braunerseuther F Mach, Trends Cardiovasc Med 2005 15 202 206 10.1016/j.tcm.2005.07.002 16182129
10. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Y Ichida G Hasegawa M Fukui H Obayashi M Ohta A Fujinami K Ohta K Nakano T Yoshikawa N Nakamura, Pharmacology 2006 76 34 39 10.1159/000088948 16227702
11. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappa B-dependnet pathway. N Silswal AK Singh B Aruna S Mukhopadhyay S Ghosh NZ Ehtesham, Biochem Biophys Res Commun 2005 334 1092 1101 10.1016/j.bbrc.2005.06.202 16039994
12. The molecular regulation of resistin expression in cultured vascular smooth muscle cells under hypoxia. HF Hung BW Wang H Chang KG Shyu, J Hypertens 2008 26 2349 2360 10.1097/HJH.0b013e328311fa30 19008713
13. The adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. MW Rajala PE Scherer, Endocrinology 2003 144 3765 3773 10.1210/en.2003-0580 12933646
14. Regulation of fasted blood glucose by resistin. RR Banerjee SM Rangwala JS Shapiro AS Rich B Rhoades Y Qi J Wang MW Rajala A Pocai PE Scherer CM Steppan RS Ahima S Obici L Rossetti MA Lazar, Science 2004 303 1195 1198 10.1126/science.1092341 14976316
15. Resistin worsens cardiac ischemia-reperfusion injury. SE Rothwell AM Richards CJ Pemberton, Biochem Biophys Res Commun. 2006 349 1 4000 4007 10.1016/j.bbrc.2006.08.052
16. Resistin is an inflammatory marker of atherosclerosis in humans. MP Reilly M Lehrke ML Wolfe A Rohatgi MA Lazar DJ Rader, Circulation 2005 111 932 939 10.1161/01.CIR.0000155620.10387.43 15710760
17. Plasma resistin levels correlate with determinants of the metabolic syndrome. GD Norata M Ongari K Garlaschelli S Raselli L Grigore AL Catapano, Eur J Endocrinol 2007 156 279 284 10.1530/eje.1.02338 17287419
18. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. E Lubos CM Messow R Schnabel HJ Rupprecht C Espinola-Klein C Bickel D Peetz F Post K Lackner L Tiret T Munzel S Blankenberg, Atherosclerosis 2007 193 121 128 10.1016/j.atherosclerosis.2006.05.039 16814296
19. Resistin induces lipolysis and re-esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophages. C Rac SA Roberston JM Taylor A Graham, FEBS Lett 2007 581 4877 4883 10.1016/j.febslet.2007.09.014 17889853
20. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. G Shetty PA Economides ES Horton CS Mantzoros A Veves, Daibetes Care 2004 27 2450 2457 10.2337/diacare.27.10.2450
21. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. C Otto RJ Frost M Vogeser AF Pfeiffer J Spranger KG Parhofer, Acta Diabetol 2007 44 65 68 10.1007/s00592-007-0244-8 17530469
22. Short-term ttreatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. I Gouni-Berthold HK Berthold JP Chamberland W Krone CS Mantzoros, Clin Endocrinol 2008 68 536 541 10.1111/j.1365-2265.2007.03080.x
23. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. WL Hu SB Qian JJ Li, Cytokine 2007 40 201 206 10.1016/j.cyto.2007.09.011 18023360